Undersøkelse, nytt bruksområde for Hexvix.

"Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

PURPOSE: No reliable methods currently exist to predict patient response to intravesical immunotherapy with bacillus Calmette-Guérin given after transurethral resection for high risk nonmuscle invasive bladder cancer.

CONCLUSIONS: Fluorescence in situ hybridization results can identify patients at risk for tumor recurrence and progression during bacillus Calmette-Guérin immunotherapy. This information may be used to counsel patients about alternative treatment strategies."

To viktige artikler. Første fra 2009:

"Economic aspects of bladder cancer: what are the benefits and costs?"

"The researchers in that study estimated that, in using PDD, they have avoided at least 20 additional TURBs over a 5-year follow-up, clearly demonstrating that the benefits associated with PDD outweigh the costs"

Economic aspects of bladder cancer: what are the benefits and costs?


Nytt studie, men her har jeg lite informasjon enda. Jeg venter på et gjennombrudd der Hexvix blir standard.

"WCE 2011 - Prospective evaluation of routine fluorescence cystoscopy demonstrates significantly increased CIS detection - Session Highlights"

"KYOTO, JAPAN (UroToday.com) - A group from the University of Tuebingen, Germany presented another interesting abstract in which they prospectively evaluated the impact of routine use of fluorescence cystoscopy (PDD) in diagnosing urothelial carcinoma in situ (CIS)."

Prospective evaluation of routine fluorescence cystoscopy demonstrates significantly increased CIS detection